Testimony before the FDA’s Cardiovascular and Renal Drugs Advisory Committee Regarding the Drug Cangrelor
Public Citizen strongly opposes approval of the anti-platelet drug cangrelor for use in patients undergoing coronary artery stenting. The key clinical trial failed to show that cangrelor is as safe and effective as other available treatments for these uses, and the design of the trial was unethical because subjects assigned to the control group received substandard anti-platelet management. The FDA again should reject the drug, as it did one year ago.